Skip to main content
VCbacked
Log inGet Started

Eupraxia Pharmaceuticals

Victoria, Canada

Eupraxia is a clinical-stage biotech company developing locally delivered, extended-release alternatives to currently approved drugs.

$63.2M raised
Feb 2026
Post-IPO Equity
BiotechnologyHealth CareMedicalPharmaceutical

Top Investors

Silicon Valley BankYabema Capital

Founder Contacts

30,000+ verified contacts
Get Instant Access

Emails, phones & LinkedIn profiles

Frequently Asked Questions about Eupraxia Pharmaceuticals

How much funding has Eupraxia Pharmaceuticals raised?
Eupraxia Pharmaceuticals has raised $63.2M in total funding. The most recent round was Post-IPO Equity. The last funding was announced in February 2026.
Who are Eupraxia Pharmaceuticals's investors?
Eupraxia Pharmaceuticals's investors include Silicon Valley Bank, Yabema Capital.
Where is Eupraxia Pharmaceuticals headquartered?
Eupraxia Pharmaceuticals is headquartered in Victoria, Canada.
What does Eupraxia Pharmaceuticals do?
Eupraxia is a clinical-stage biotech company developing locally delivered, extended-release alternatives to currently approved drugs.
What stage is Eupraxia Pharmaceuticals at?
Eupraxia Pharmaceuticals is at the Post-IPO Equity stage.
Cite this page

Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .

MLA
"Eupraxia Pharmaceuticals — Funding & Investors." VCBacked, February 19, 2026, https://www.vcbacked.co/company/eupraxia-pharmaceuticals. Accessed July 2, 2026.
APA
VCBacked. (2026). Eupraxia Pharmaceuticals — Funding & Investors. Retrieved July 2, 2026, from https://www.vcbacked.co/company/eupraxia-pharmaceuticals
Wikipedia (cite web)
{{cite web |title=Eupraxia Pharmaceuticals — Funding & Investors |url=https://www.vcbacked.co/company/eupraxia-pharmaceuticals |website=VCBacked |access-date=July 2, 2026}}

Profile data sourced and verified per the VCBacked methodology. Last funding round dated .

Similar Companies in Biotechnology

View all
Rapport Therapeutics
Boston$250.0M
Renaissance BioScience
Vancouver$599K
Allterum Therapeutics
Houston$1.0M
AlpalifeBio
Woburn$9.8M
Epsilogen
London$16.3M
Advanced Microbiome Interventions
Amsterdam$300K